"Hypolipidemic Agents" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Substances that lower the levels of certain LIPIDS in the BLOOD. They are used to treat HYPERLIPIDEMIAS.
| Descriptor ID |
D000960
|
| MeSH Number(s) |
D27.505.519.186.071 D27.505.954.557.500
|
| Concept/Terms |
Hypolipidemic Agents- Hypolipidemic Agents
- Agents, Hypolipidemic
- Antihyperlipidemics
- Hypolipidemic Drugs
- Drugs, Hypolipidemic
- Antilipemic Drugs
- Drugs, Antilipemic
- Antilipemics
- Antihyperlipemics
- Antilipemic Agents
- Agents, Antilipemic
|
Below are MeSH descriptors whose meaning is more general than "Hypolipidemic Agents".
Below are MeSH descriptors whose meaning is more specific than "Hypolipidemic Agents".
This graph shows the total number of publications written about "Hypolipidemic Agents" by people in this website by year, and whether "Hypolipidemic Agents" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1996 | 1 | 0 | 1 |
| 2000 | 1 | 1 | 2 |
| 2001 | 2 | 0 | 2 |
| 2002 | 0 | 4 | 4 |
| 2003 | 0 | 2 | 2 |
| 2004 | 1 | 0 | 1 |
| 2005 | 2 | 3 | 5 |
| 2006 | 2 | 3 | 5 |
| 2007 | 2 | 2 | 4 |
| 2008 | 1 | 1 | 2 |
| 2009 | 3 | 0 | 3 |
| 2010 | 0 | 1 | 1 |
| 2011 | 2 | 2 | 4 |
| 2012 | 0 | 1 | 1 |
| 2013 | 3 | 0 | 3 |
| 2014 | 3 | 2 | 5 |
| 2015 | 2 | 0 | 2 |
| 2016 | 1 | 2 | 3 |
| 2017 | 3 | 4 | 7 |
| 2018 | 0 | 2 | 2 |
| 2019 | 1 | 0 | 1 |
| 2020 | 2 | 1 | 3 |
| 2021 | 3 | 0 | 3 |
To return to the timeline,
click here.
Below are the most recent publications written about "Hypolipidemic Agents" by people in Profiles.
-
Human Angiopoietin-like Protein 3/ANGPTL3 Antibodies: Adding to the Armamentarium in the Management of Dyslipidemia. J Cardiovasc Pharmacol. 2021 11 01; 78(5):e631-e640.
-
Relationship of low molecular weight fluorophore levels with clinical factors and fenofibrate effects in adults with type 2 diabetes. Sci Rep. 2021 09 21; 11(1):18708.
-
The relationship of neutrophil elastase and proteinase 3 with risk factors, and chronic complications in type 2 diabetes: A Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) sub-study. Diab Vasc Dis Res. 2021 Jul-Aug; 18(4):14791641211032547.
-
Effects of Modified Low-Density Lipoproteins and Fenofibrate on an Outer Blood-Retina Barrier Model: Implications for Diabetic Retinopathy. J Ocul Pharmacol Ther. 2020 12; 36(10):754-764.
-
Relationships of adipocyte-fatty acid binding protein and lipocalin 2 with risk factors and chronic complications in type 2 diabetes and effects of fenofibrate: A fenofibrate Intervention and event lowering in diabetes sub-study. Diabetes Res Clin Pract. 2020 Nov; 169:108450.
-
Uric acid predicts long-term cardiovascular risk in type 2 diabetes but does not mediate the benefits of fenofibrate: The FIELD study. Diabetes Obes Metab. 2020 08; 22(8):1388-1396.
-
Future perspectives of the pharmacological management of diabetic dyslipidemia. Expert Rev Clin Pharmacol. 2019 Feb; 12(2):129-143.
-
Recommendations to Enhance Pediatric Cardiovascular Drug Development: Report of a Multi-Stakeholder Think Tank. J Am Heart Assoc. 2018 02 10; 7(4).
-
CONSENSUS STATEMENT BY THE AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS AND AMERICAN COLLEGE OF ENDOCRINOLOGY ON THE COMPREHENSIVE TYPE 2 DIABETES MANAGEMENT ALGORITHM - 2018 EXECUTIVE SUMMARY. Endocr Pract. 2018 01; 24(1):91-120.
-
Triglyceride-lowering trials. Curr Opin Lipidol. 2017 Dec; 28(6):477-487.